# Global clinical trial contract wins in Alzheimer’s Disease  and Friedreich’s Ataxia

12 Sep 25

news

# Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia

Alzheimer's disease

Friedreich's Ataxia

[  ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/global-clinical-trial-contract-wins-in-alzheimers-disease-and-friedreichs-ataxia/) [  ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/global-clinical-trial-contract-wins-in-alzheimers-disease-and-friedreichs-ataxia/) [  ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/global-clinical-trial-contract-wins-in-alzheimers-disease-and-friedreichs-ataxia/) [  ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/global-clinical-trial-contract-wins-in-alzheimers-disease-and-friedreichs-ataxia/) <a class="trigger-share-window d-md-none">  </a>

**12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO**, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications. The combined value of the new contracts is circa £1.3 million.

Under the first contract IXICO will provide trial management and imaging analysis for a Phase 1 Alzheimer’s Disease (AD) clinical trial by a major pharmaceutical company. The contract scope covers a collaboration for approximately three and a half years.

The second contract with a US-based biotech sees IXICO facilitating high quality imaging data collection for a Phase 1b trial to aid surgical planning in Friedreich's Ataxia (FA), a progressive inherited neurodegenerative disorder that effects the nervous system and heart. The contract scope covers a collaboration for six years.

This positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

Bram Goorden, CEO of IXICO, commented: "The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space. The two deals hit different key elements of our strategy, respectively supporting Alzheimer’s as a core indication, and; maintaining our leadership position in the rare CNS disease space.”

**For further information please contact:**

**IXICO plc**

+44 (0) 20 3763 7499

Grant Nash, Chief Financial Officer

James Chandler, Chief Business Officer

info@ixico.com

**Cavendish Capital Markets Limited**

(Nominated Adviser and Sole Broker)

+44 (0) 20 7220 0500

Giles Balleny (Corporate Finance)

Nigel Birks (Healthcare Specialist Sales)

Harriet Ward (Corporate Broking)

Michael F Johnson (Sales)

 

[ Back to News  ](/news-and-resources/news/)

### Recents

![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)

2 Nov 26

news

[IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/)

[IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/)

[IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/)

[IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/)

[IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/)

### Library

[November 2026](/news-and-resources/news/archive/2026/11/)

[October 2026](/news-and-resources/news/archive/2026/10/)

[September 2026](/news-and-resources/news/archive/2026/09/)

[July 2026](/news-and-resources/news/archive/2026/07/)

[June 2026](/news-and-resources/news/archive/2026/06/)

[May 2026](/news-and-resources/news/archive/2026/05/)

[April 2026](/news-and-resources/news/archive/2026/04/)

[March 2026](/news-and-resources/news/archive/2026/03/)

[February 2026](/news-and-resources/news/archive/2026/02/)

[January 2026](/news-and-resources/news/archive/2026/01/)

[2025](/news-and-resources/news/archive/2025/)

[2024](/news-and-resources/news/archive/2024/)

[2023](/news-and-resources/news/archive/2023/)

[2022](/news-and-resources/news/archive/2022/)

[2021](/news-and-resources/news/archive/2021/)

[2020](/news-and-resources/news/archive/2020/)

[2019](/news-and-resources/news/archive/2019/)
